StockNews.AI
LUNG
StockNews.AI
181 days

Pulmonx Reports Record Fourth Quarter and Full Year 2024 Financial Results

1. Pulmonx's 2024 revenue reached $83.8M, a 22% annual increase. 2. Q4 2024 revenue hit $23.8M, up 23% year-over-year. 3. U.S. revenue in 2024 rose to $56.5M, a 23% growth. 4. Gross margin remained strong at 74% for both Q4 and full year.

Earnings
+32.23%Current Return
VS
-0.39%S&P 500
$6.6402/19 04:08 PM EDTEvent Start
$8.7802/20 10:26 PM EDTLatest Updated
17m saved
Insight
Article

FAQ

Why Bullish?

Record revenue growth and a solid gross margin typically support stock appreciation. Prior instances show improved earnings led to significant price gains.

How important is it?

The article details key financial metrics that directly reflect Pulmonx's operational health and market strategy, influencing investor sentiment significantly.

Why Long Term?

Sustained revenue growth and operational efficiency should positively drive LUNG's long-term valuation.

Related Companies

LUNGCOPD
REDWOOD CITY, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered $83.8 million in worldwide revenue for the full year of 2024, a 22% increase over the prior yearAchieved record worldwide revenue of $23.8 million for the fourth quarter of 2024, a 23% increase over the same period last year on an as reported and constant currency basisSet a record of $15.9 million and $56.5 million in U.S. revenue for the fourth quarter 2024 and the full year 2024, representing 16% and 23% year-over-year growth, respectivelyRealized gross margin of 74% in the fourth quarter of 2024 and 74% for the full year of 2024Added 11 new Zephyr® Valve U.S. treatment centers in the fourth quarter of 2024Partnered with American Lung Association to launch new educational initiatives for COPD patients and providersImplemented LungTraX™ software platform in first U.S. pilot sites “Our record quarterly and full year results underscore the continued success of our focused strategy and execution in further expanding our account base, optimizing patient workflows, and raising awareness among both patients and referring physicians,” said Steve Williamson, President & Chief Executive Officer. “With strong underlying demand and ongoing momentum, particularly with the pilot launch of the LungTraX software platform, we are confident in our ability to drive long-term, sustainable growth in 2025 and beyond.” Fourth Quarter 2024 Financial ResultsTotal worldwide revenue in the fourth quarter of 2024 was $23.8 million, a 23% increase from $19.3 million in the fourth quarter of 2023 and an increase of 23% on a constant currency basis. U.S. revenue was $15.9 million, a 16% increase from the fourth quarter of 2023. International revenue was $7.9 million, a 42% increase compared to the fourth quarter of 2023, and a 40% increase on a constant currency basis. Gross profit in the fourth quarter of 2024 was $17.6 million, compared to $14.4 million for the fourth quarter of 2023. Gross margin for the fourth quarter of 2024 was 74%, compared to 75% for the same period in 2023. Operating expenses in the fourth quarter of 2024 were $31.0 million, compared to $28.3 million for the fourth quarter of 2023, representing an increase of 9%. The increase in operating expenses was primarily attributable to continued investments in our commercial activities and higher clinical expenses. Net loss in the fourth quarter of 2024 was $13.2 million, or $0.33 per share, compared to a net loss of $13.9 million, or $0.36 per share, for the same period in 2023. Adjusted EBITDA loss in the fourth quarter of 2024 was $7.5 million compared to $8.4 million for the same period in 2023. Full Year 2024 Financial ResultsTotal worldwide revenue for the full year of 2024 was $83.8 million, a 22% increase from $68.7 million for the full year of 2023 and an increase of 22% on a constant currency basis. U.S. revenue was $56.5 million, a 23% increase from $45.9 million for the full year of 2023. International revenue was $27.3 million, a 20% increase from $22.8 million for the full year of 2023, and a 19% increase on a constant currency basis. The growth in revenue reflects continued commercial momentum and adoption of Zephyr Valve procedures. Gross profit for the full year of 2024 was $62.0 million, a 22% increase compared to $50.8 million for the full year of 2023. Gross margin for the full year of 2024 was 74%, approximately in line with the prior year. Operating expenses for the full year of 2024 were $119.7 million, compared to $112.7 million for the full year of 2023, representing an increase of 6%. The increase in operating expenses was primarily attributable to continued investments in our commercial activities and clinical development costs related to our AeriSeal program. Net loss for the full year of 2024 was $56.4 million, or $1.44 per share, compared to a net loss of $60.8 million, or $1.60 per share, for the same period in 2023. Adjusted EBITDA loss for the full year of 2024 was $31.3 million compared to $39.0 million for the full year of 2023. Cash, cash equivalents, and marketable securities totaled $101.5 million as of December 31, 2024. Full Year 2025 Financial GuidancePulmonx expects revenue for the full year 2025 to be in the range of $96 million to $98 million, representing growth of 15% to 17% compared to 2024, or 16% to 18% on a constant currency basis, as our guidance assumes a negative impact from foreign exchange on reported revenue growth of approximately 100 basis points. The Company expects gross margin for the full year 2025 to be approximately 74%. Pulmonx expects total operating expenses for the full year 2025 to fall within the range of $133 million to $135 million, inclusive of approximately $22 million of non-cash stock-based compensation. Webcast and Conference Call DetailsPulmonx will host a conference call today, February 19, 2025, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its fourth quarter and full year 2024 financial results and to discuss its full year 2025 financial guidance. A live webcast of the conference call will be available on the Investor Relations section of the Company's website at https://investors.pulmonx.com/. The webcast will be archived on the website following the completion of the call. Use of Non-GAAP Financial MeasuresTo supplement Pulmonx’s condensed consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, Pulmonx provides certain non-GAAP financial measures in this release as supplemental financial metrics. Non-GAAP financial measures reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results, may provide a more complete understanding of factors and trends affecting Pulmonx’s business. Constant currency calculations show reported current period revenues as if the foreign exchange rates remain the same as those in effect in the comparable prior year period. Pulmonx uses results on a constant currency basis as one measure to evaluate its performance. Pulmonx calculates constant currency by calculating current-year results using foreign currency exchange rates from the applicable comparable period in the prior year. Pulmonx generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. Pulmonx believes the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand its operating results and evaluate its performance in comparison to prior periods. Pulmonx generally uses constant currency to facilitate management's financial and operational decision-making, including evaluation of Pulmonx’s historical operating results. The Company defines Adjusted EBITDA as earnings before interest income or expense, taxes, depreciation and amortization and stock-based compensation and may also exclude certain non-recurring, irregular or one-time items not reflective of our ongoing core business operations. Management believes in order to properly understand short-term and long-term financial trends, investors may wish to consider the impact of these excluded items in addition to GAAP measures. Further, management uses adjusted EBITDA for strategic and annual operating planning. We believe these non-GAAP financial measures are useful as a supplement in evaluating our ongoing operational performance and enhancing an overall understanding of our past financial performance. Reconciliation of non-GAAP financial measures to the most comparable GAAP measures for the fourth quarter and full year ended December 31, 2024 and 2023 is set forth in the tables below. The non-GAAP financial measures used by Pulmonx should be considered supplemental to, and not a substitute for, financial information prepared in accordance with GAAP. Because non-GAAP financial measures exclude the effect of items that increase or decrease the company's reported results of operations, management strongly encourages investors to review, when they become available, the Company's consolidated financial statements and publicly filed reports in their entirety. The Company's definition of non-GAAP measures may differ from similarly titled measures used by others. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect our strategy, operations or financial performance, and actual results may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. These forward-looking statements include, but are not limited to, statements regarding our strategy and execution in further optimizing patient workflows, and raising awareness among both patients and referring physicians, our expectations regarding demand and ongoing momentum, including with respect to the pilot launch of the LungTraX software platform, our ability to drive long-term, sustainable growth in 2025 and beyond, our possible or assumed future results of operations, including long-term outlook, descriptions of our revenues, total operating expenses, gross margin, guidance for full year 2025, and overall business strategy. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release can be found in the Risk Factors section of our filings with the Securities and Exchange Commission (“SEC”), including our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the SEC on November 1, 2024, available at www.sec.gov. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical fact are forward-looking statements. Except to the extent required by law, we undertake no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business. About Pulmonx CorporationPulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTraX™ Platform, and StratX® Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.  Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.   Investor ContactBrian JohnstonLaine MorganGilmartin Groupinvestors@pulmonx.com  Pulmonx CorporationConsolidated Statements of Operations(in thousands, except share and per share data)(Unaudited)       Three Months Ended December 31, Twelve Months Ended December 31,  2024 2023 2024 2023Revenue $23,765  $19,278  $83,789  $68,675 Cost of goods sold  6,175   4,878   21,788   17,923 Gross profit  17,590   14,400   62,001   50,752 Operating expenses        Research and development  4,001   3,896   17,570   18,080 Selling, general and administrative  27,006   24,423   102,135   94,607 Total operating expenses  31,007   28,319   119,705   112,687 Loss from operations  (13,417)  (13,919)  (57,704)  (61,935)Interest income  1,045   1,541   5,061   5,568 Interest expense  (842)  (905)  (3,507)  (3,232)Other income (expense), net  77   (357)  256   (673)Net loss before tax  (13,137)  (13,640)  (55,894)  (60,272)Income tax expense  38   248   500   571 Net loss $(13,175) $(13,888) $(56,394) $(60,843)Net loss per share attributable to common stockholders, basic and diluted $(0.33) $(0.36) $(1.44) $(1.60)Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted  39,581,760   38,377,404   39,111,073   37,974,567                    Pulmonx CorporationCondensed Consolidated Balance Sheets(in thousands)(Unaudited)     December 31, 2024 December 31, 2023Assets   Current assets   Cash and cash equivalents$70,905  $83,547 Restricted cash 257   237 Short-term marketable securities 30,577   33,555 Accounts receivable, net 13,120   12,105 Inventory 16,915   16,743 Prepaid expenses and other current assets 4,474   4,235 Total current assets 136,248   150,422 Long-term marketable securities —   14,390 Long-term inventory 1,681   2,580 Property and equipment, net 2,907   4,028 Goodwill 2,333   2,333 Intangible assets, net —   31 Right of use assets 18,545   3,406 Other long-term assets 1,136   591 Total assets$162,850  $177,781     Liabilities and Stockholders' Equity   Current liabilities   Accounts payable$3,827  $1,497 Accrued liabilities 16,472   16,234 Income taxes payable 49   93 Deferred revenue 135   104 Short-term debt 3,176   2,155 Current lease liabilities 778   3,074 Total current liabilities 24,437   23,157 Deferred tax liability 87   114 Long-term lease liabilities 18,515   1,106 Long-term debt 34,002   35,089 Total liabilities 77,041   59,466 Stockholders' equity   Common stock 40   39 Additional paid-in capital 551,211   526,797 Accumulated other comprehensive income 2,113   2,640 Accumulated deficit (467,555)  (411,161)Total stockholders' equity 85,809   118,315 Total liabilities and stockholders' equity$162,850  $177,781           Pulmonx CorporationReconciliation of Reported Revenue % Change to Constant Currency Revenue % Change(in thousands)(Unaudited)         Three Months Ended December 31,       2024 2023 % Change FX Impact % Constant Currency % ChangeUnited States$15,879  $13,720  15.7% —% 15.7%International 7,886   5,558  41.9% 2.2% 39.7%Total$23,765  $19,278  23.3% 0.7% 22.6%  Twelve Months Ended December 31,       2024 2023 % Change FX Impact % Constant Currency % ChangeUnited States$56,465  $45,917  23.0% —% 23.0%International 27,324   22,758  20.1% 1.2% 18.9%Total$83,789  $68,675  22.0% 0.4% 21.6%            Pulmonx CorporationReconciliation of Net Loss to Non-GAAP Adjusted EBITDA(in thousands)(Unaudited)     Three Months Ended December 31, Twelve Months Ended December 31, 2024 2023 2024 2023GAAP Net loss$(13,175) $(13,888) $(56,394) $(60,843)Depreciation and amortization 294   287   1,493   1,548 Stock-based compensation 5,523   5,598   22,955   22,101 Impairment of capitalized software development costs —   —   1,717   — Interest (income)/expense, net (203)  (636)  (1,554)  (2,336)Provision for income taxes 38   248   500   571 Adjusted EBITDA$(7,523) $(8,391) $(31,283) $(38,959)                

Related News